Dr Hardesty on Updated Data With Frontline Niraparib Plus Bevacizumab Maintenance in Advanced Ovarian Cancer

"Across all comers, we saw really favorable OS [outcomes] compared with [those seen in] some other publications looking at similar groups of patients. Not surprisingly, we saw that the results [were even better] for patients who were either HRD or [displayed] a BRCAmutation."

Melissa M. Hardesty, MD, a managing partner at Alaska Women’s Cancer Center, discusses overall survival (OS) outcomes with the combination of niraparib (Zejula) and bevacizumab (Avastin) as maintenance therapy for patients with newly diagnosed advanced ovarian cancer who responded to frontline platinum-based chemotherapy.

Updated OS data from the phase 2 OVARIO trial (NCT03326193) were presented during the 2025 SGO Annual Meeting on Women’s Cancer and showed that OS outcomes with the combination of niraparib and bevacizumab were durable in patients with newly diagnosed advanced ovarian cancer who had responded to frontline platinum-based chemotherapy and that the regimen did not adversely affect health-related quality of life, Hardesty stated. At the data cutoff date of August 12, 2024, and a median follow-up of 65.7 months, the median OS in the overall population (n = 105) was 61.1 months (95% CI, 44.9-not evaluable [NE]), with data maturity for OS reaching 52.4%, Hardesty reported. These results showed favorable OS outcomes when compared with those observed in previous studies involving similar patient populations, Hardesty commented.

The study also provided insights into OS outcomes based on biomarker status, Hardesty explained. As expected, patients with homologous recombination deficiency (HRD) or a BRCA mutation had superior OS outcomes compared with those without these biomarkers, Hardesty highlighted.

In the HRD population (n = 49), the median OS was NE (95% CI, 58.2-NE), Hardesty stated. Among those in the HRD population with BRCA-mutant (n = 29) and wild-type (n = 16) disease, the median OS was 68.3 months (95% CI, 52.5-NE) and NE (95% CI, 38.6-NE), respectively, Hardesty observed. The median OS in the homologous recombination–proficient population (n = 38) was 38.7 months (95% CI, 21.9-63.8), Hardesty reported. In the population of patients with undetermined homologous recombination status (n = 18), the median OS was 39.8 months (95% CI, 21.7-NE), Hardesty stated. Finally, in the overall population, among patients with BRCA-mutant (n = 29) and wild-type (n = 67) disease, the median OS was 68.3 months (95% CI, 52.5-NE) and 53.5 months (95% CI, 33.5-NE), respectively, Hardesty concluded.